1. Home
  2. TXMD vs PHGE Comparison

TXMD vs PHGE Comparison

Compare TXMD & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TXMD
  • PHGE
  • Stock Information
  • Founded
  • TXMD 2008
  • PHGE 2015
  • Country
  • TXMD United States
  • PHGE Israel
  • Employees
  • TXMD N/A
  • PHGE N/A
  • Industry
  • TXMD Biotechnology: Pharmaceutical Preparations
  • PHGE Biotechnology: Pharmaceutical Preparations
  • Sector
  • TXMD Health Care
  • PHGE Health Care
  • Exchange
  • TXMD Nasdaq
  • PHGE Nasdaq
  • Market Cap
  • TXMD 13.1M
  • PHGE 11.1M
  • IPO Year
  • TXMD N/A
  • PHGE N/A
  • Fundamental
  • Price
  • TXMD $1.16
  • PHGE $0.61
  • Analyst Decision
  • TXMD
  • PHGE Strong Buy
  • Analyst Count
  • TXMD 0
  • PHGE 2
  • Target Price
  • TXMD N/A
  • PHGE $22.50
  • AVG Volume (30 Days)
  • TXMD 18.0K
  • PHGE 73.2K
  • Earning Date
  • TXMD 11-12-2024
  • PHGE 11-14-2024
  • Dividend Yield
  • TXMD N/A
  • PHGE N/A
  • EPS Growth
  • TXMD N/A
  • PHGE N/A
  • EPS
  • TXMD N/A
  • PHGE N/A
  • Revenue
  • TXMD $1,596,000.00
  • PHGE N/A
  • Revenue This Year
  • TXMD $605.07
  • PHGE N/A
  • Revenue Next Year
  • TXMD $1.11
  • PHGE N/A
  • P/E Ratio
  • TXMD N/A
  • PHGE N/A
  • Revenue Growth
  • TXMD N/A
  • PHGE N/A
  • 52 Week Low
  • TXMD $1.10
  • PHGE $0.48
  • 52 Week High
  • TXMD $2.75
  • PHGE $8.55
  • Technical
  • Relative Strength Index (RSI)
  • TXMD 29.78
  • PHGE 42.68
  • Support Level
  • TXMD $1.10
  • PHGE $0.61
  • Resistance Level
  • TXMD $1.30
  • PHGE $0.69
  • Average True Range (ATR)
  • TXMD 0.06
  • PHGE 0.08
  • MACD
  • TXMD -0.01
  • PHGE 0.01
  • Stochastic Oscillator
  • TXMD 21.21
  • PHGE 10.05

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

Share on Social Networks: